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Sinus Valsalva aneurysm (SVA) is a structural abnormality which constitutes 1-2 % of all congenital heart diseases. It is more frequently seen in male gender, and Asian populations. A congenital defect situated between an elastic lamina in Valsalva sinus over the aortic valve ring, and muscular tissue is held responsible for the development of this aneurysm. [1, 2] SVA is mostly (80-85 %) originates from the right coronary sinus, then non-coronary sinus (5-15 %), and rarely from the left coronary sinus. A 40-75 % of SVAs can rupture with time. Aneurysms mostly rupture into the right atrium and/or right ventricle, and seen mostly in patients aged 20-40 years
. [3] Classical treatment of ruptured SVA is surgical treatment. The outcomes of the surgical treatment are generally satisfactory, however risk of in-patient mortality (1.5-3.9 % ),and stroke (1.6 %) still exists besides, recurrent SVA, and aortic insufficiency might develop. [4, 5] In recent years various devices used for the percutaneous treatment of congenital heart diseases as atrial septal defect (ASD), and patent ductus arteriosus (PDA) have also been successful in the management of ruptured SVAs, and these treatment modalities have been reported as proper alternatives to surgery in appropriate cases. [6] In this article, a case with a ruptured SVA with double orifices arising from the right coronary sinus, and extending from aorta into the right ventricle which was closed percutaneously using Amplatzer Duct Occluder I (ADO I) device was presented.
CASE PRESENTATION
A 30-year-old male patient consulted to our outpatient clinics with complaints of exertional palpation, dyspnea, and stabbing chest for the last 2 months. His physical examination findings were as follows: arterial blood pressure, 140/60 mm Hg; pulse rate 95 /min, and body temperature, 36.5 ºC. Cardiovascular system examination revealed a mild venous congestion, and a thrill was heard along the right edge of sternum in the 5 th intercostal space. Besides .fixed splitting of the 2 nd heart sound, and continuous systolicdiastolic murmur starting from the aortic focus spreading to the neck, and back along the right edge of the sternum was heard. Bounding, and strong femoral arterial pulsation was also auscultated.
Transthoracic (TTE), and transesophageal echocardiographic (TOE) examinations revealed an aneurysmatic right Valsalva sinus, and colour-Doppler ultrasonographic examination of the same region demonstrated a passage (a shunt) into the right ventricle (Figure 1a, b) . On echocardiograms left -to -right shunt ratio was estimated as 3. On aortograms of the patient, two defects were observed. The large defect allowed passage of diffuse radioopaque material from the right Valsalva sinus into the right ventricle, and through the second defect lesser amount of contrast material passed. This left-to -right shunt ratio was 3.8 based on oximetric assessments ( Figure 2a ). With available findings, diagnosis of a sinus Valsalva aneurysm ruptured from aorta into the right ventricle was made. Aortograms, and echocardiograms of the patient were evaluated, and anatomic location, and dimensions (aortic edge of the main defect was 8 mm, and its length 6mm) of the defect were found to be suitable for percutaneous management. The patient was informed about surgical, and percutaneous treatment modalities. After written consent of the patient was obtained, firstly closure of the larger, and then the smaller defect were planned in two sessions.
Both femoral regions were desensitized with local anesthesia. Using Judkins technique 6 French (F) delivery sheaths were inserted into the right femoral vein, and left femoral vein to establish required patent arterial, and venous access sites. Then heparin (50 IU/kg), and cefazoline sodium (2 g IV) were administered. A 6 Fr multi-purpose (Cordis) catheter was advanced with the aid of Terimo guidewire through femoral artery to reach ruptured SVA. The catheter was then passed through the right ventricle into the right atrium. Amplatzer Superstiff Straight (Boston Scientific, USA) guidewire (0.89 x 235 cm) was replaced with Terimo guidewire , and advanced through vena cava superior. Then muli-purpose catheter was withdrawn. Goose Neck retractor (10 mm, Microvenna, MN, ABD) was advanced intravenously into superior vena cava. At this level, Amplatzer Superstiff Straight guidewire was grasped, and removed from inside its femoral vein delivery sheath.to provide necessary arterivenous route for the implantation of ADO 1 device (Figure 2b ). With the aid of a guidewire an 8 Fr-catheter was passed via intravenous route, and advanced through the right ventricle, and ruptured SVA site till it turned around the aortic arch. After removal of the guidewire, ADO I device (9-PDA-004, disc diameter 10 mm, length 7 mm and diameter 6 mm) loaded on the delivery system was advanced inside 8 Fr catheter till retention disc of the device was extruded beyond the distal end of the delivery sheath. Catheter together with the device was retracted from inside aortic arch. When the retention disc was engaged on the the ruptured site, delivery system was held stable, and the catheter was retracted further to enable complete opening of the device. Meanwhile echocardiographic, and aortographic images were obtained from different angles to evaluate the position of the device and preswence of leakage (if any) . To determine if the device was engaged accurately in the ruptured site Minnesota manoeuvre was performed, and the device was left in situ after ideal location of the device was confirmed. Recorded images reviewed, and closure of the targeted defect, and continuous passage through the other defect were observed. (Figure 2c, d) . Total duration of the procedure, and fluoroscopic examination was 60, and 30 min., respectively. The patient was followed up for 6 months without development of any complication. At the end of the follow-up period invasive imaging, and hemodynamic studies were performed as planned beforehand. Lack of any passage through the firstly closed defect site, and regression of shunt ratio to 1.7 were observed. Meanwhile, aortic insufficiency did not deteriorate. Aortic edge (6 mm) , and length (5mm) of the other defect site which allowed continuous passage were also determined as indicated in parentheses. Since dimensions, and anatomic location of the defect were deemed to be suitable for percutaneous management, we planned to close the defect with ADO I device used for the first procedure The device was positioned on the defect size as described for the first procedure (Figure 3a) . Posttprocedural images recorded demonstrated that both devices were positioned correctly. Postoperative aortograms displayed a markedly decreased passage from aorta into the right ventricle which was maintained at an acceptable level for the procedural success. (Figure 3b-d) . The position of the devices was evaluated in control TTE performed one day later . Since any procedural complication was not observed, the patient was discharged with recommendation of dual antiplatelet drug therapy, and infective endocarditis prophylaxis to be maintained for one year. of ADO device in the management of selected cases of ruptured SVAs as an alternative to surgical treatment. [7] Before percutaneous treatment of ruptured SVAs, detailed evaluation of the patient as for other concomitant cardiovascular abnormalities is very important. The presence of additional anomalies can unfavourable effect the procedural success, and enhance the risk of postprocedural complications. Though larger patient series reporting treatment outcomes of ruptured SVAs using ADO devices have not been conducted yet, a 90 % procedural success rate has been indicated in available case reports, and small case series.. [8] Although rupture of SVA stemmimg from the right, and non-coronary sinus is suitable for percutaneous treatment, its communication with aortic leaflets, tricuspid valves, and coronary arteries are other factors effecting the procedural success rates. Selection of appropriate sized ADO devices is also important for the procedural success. Stabilization of the ADO device to be used for percutaneous closure on the defect site, use of devices 2-3 mm larger than the diameter of the defect is recommended. [9] In our case, because of absence of any concomitant structural abnormality, defect sizes, and locations suitable for percutaneous closure, we planned to repair both defects using ADO I device. We reviewed. the relevant literature, and couldn't find any reported case of ruptured SVA with adjacent two defects which opened into the same heart chamber, and treated using ADO device. Since simultaneous closure of these 2 defects might trigger thrombotic complications because of potential intraaortic metal load, problems which might be encountered in the adaptation of the devices on the defect size, and exacerbation of the existing aortic insuffliciency secondary to excessive distension of the aortic ring, we planned to close these defects in two separate sessions using ADO I device. We have thought that the firstly applied device would be able to complete its endothelization , and adapt to the defect size increasing the success rate of the 2. procedure with resultant facilitation of complete closure of the ruptured site during 6 month-interval between these two procedures. In evaluations performed 6 months after the first procedure, regression of the shunt ratio to 1.7, lack of any passage through the first device as observed on aortograms or absence of any deterioration of aortic insuffliciency, markedly decreased passage from the aorta into the right ventricle after the 2 nd . procedure without development of any complication demonstrate that complicated SVAs can be managed percutaneously in compliance with predetermined appropriate strategies.
In our clinics, previously, a ruptured right SVA which opened into the right atrium had been treated using ADO I device. The patient is still at his 2 nd . postoperative year without occurrence of any adverse event. Though any complication has not been developed in any of our cases so far, in the medical literature procedural complications as right ventricular outlet obstruction, aortic insufficiency, coronary artery compression, and device-related hemolysis have been cited. [10] Following percutaneous management of ruptured SVA, antiaggregant therapy, and prophylactic treatment of infective endocarditis have been recommended. Although conclusive data about the duration of therapy do not exist, since some authors have indicated that 6-12 month-therapy could suffice, we advised our patient to maintain dual antiaggregant therapy with clopidogrel, and acetylsalycylic for 12 months. [11] Percutaneous closure devices can be reliable, and safely used as alternative methods to surgical modalities for the management of conventional ruptured SVAs, and also more complex lesions. Though this treatment yields promising short-, and longterm outcomes , for more fully determination of its clinical efficacy, long-term results of larger scale studies are awaited.
